BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-V
- Sponsors BIOTRONIK
- 16 Jan 2017 Planned End Date changed from 1 May 2020 to 1 Apr 2021.
- 18 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Apr 2017.
- 01 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.